Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking
International Immunopharmacology · 2024-11 · 141 · 113000
DOI: 10.1016/j.intimp.2024.113000 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-11. Verfasst von Ahmed Y Kira und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address: Ahmed.kira@de…. Hauptthemen laut MEDLINE: Chitosan, NLR Family, Pyrin Domain-Containing 3 Protein, Nanoparticles, NF-kappa B. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Liver inflammatory diseases are marked by serious complications. Notably, nicardipine (NCD) has demonstrated anti-inflammatory properties, but its benefits in liver inflammation have not been studied yet. However, the therapeutic efficacy of NCD is limited by its short half-life and low bioavailability. Therefore, we aimed to evaluate the potential of NCD-loaded chitosan nanoparticles (ChNPs) to improve its pharmacokinetic profile and hepatic accumulation. Four formulations of NCD-ChNPs were synthesized and characterized. The optimal formulation (NP2) exhibited a mean particle diameter of 172.6 ± 1.94 nm, a surface charge of +25.66 ± 0.93 mV, and an encapsulation efficiency of 88.86 ± 1.17 %. NP2 showed good physical stability as a lyophilized powder over three months. It displayed pH-sensitive release characteristics, releasing 77.15 ± 5.09 % of NCD at pH 6 (mimicking the inflammatory microenvironment) and 52.15 ± 3.65 % at pH 7.4, indicating targeted release in inflamed liver tissues. Pharmacokinetic and biodistribution studies revealed that NCD-ChNPs significantly prolonged NCD circulation time and enhanced its concentration in liver tissues compared to plain NCD. Additionally, the study investigated the protective effects of NCD-ChNPs in thioacetamide-induced liver injury in rats by modulating the NFκB/NLRP3/IL-1β signaling axis. NCD-ChNPs effectively inhibited NFκB activation, reduced NLRP3 inflammasome activation, and subsequent release of IL-1β, which correlated with improved hepatic function and reduced inflammation and oxidative stress. These findings highlight the potential of NCD-ChNPs as a promising nanomedicine strategy for the treatment of liver inflammatory diseases, warranting further investigation into their clinical applications, particularly in hypertensive patients with liver inflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt. Electronic address: Ahmed.kira@deltauniv.edu.eg.
- Department of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah 51452, Saudi Arabia. Electronic address: a.almarsa@qu.edu.sa.
- Biological Sciences Department, College of Science, King Faisal University, Al Ahsa 31982, Saudi Arabia; Central Laboratory, Theodor Bilharz Research Institute, Giza 12411, Egypt. Electronic address: rhamad@kfu.edu.sa.
- Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra 11961, Saudi Arabia. Electronic address: m.ahmed@su.edu.sa.
- School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M20 4BX, UK; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni Suef…
- Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. Electronic address: nouraeladle@mans.edu.eg.
Zitieren
APA
Kira, A. Y., Elmorsy, E. A., Hamad, R. S., Abdel-Reheim, M. A., Elhemely, M. A., El Adle Khalaf, N., El-Kott, A. F., AlShehri, M. A., Morsy, K., Negm, S., Mourad, A. A. E., Ramadan, A., & Saber, S. (2024). Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking. International Immunopharmacology, 141, 113000. https://doi.org/10.1016/j.intimp.2024.113000
Vancouver
Kira AY, Elmorsy EA, Hamad RS, Abdel-Reheim MA, Elhemely MA, El Adle Khalaf N, et al. Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking. International Immunopharmacology. 2024;141:113000. doi:10.1016/j.intimp.2024.113000
BibTeX
@article{Kira2024,
author = {Kira, Ahmed Y and Elmorsy, Elsayed A and Hamad, Rabab S and Abdel-Reheim, Mustafa Ahmed and Elhemely, Mai Abdallah and El Adle Khalaf, Noura and El-Kott, Attalla F and AlShehri, Mohammed A and Morsy, Kareem and Negm, Sally and Mourad, Ahmed A E and Ramadan, Asmaa and Saber, Sameh},
title = {Nicardipine-chitosan nanoparticles alleviate thioacetamide-induced acute liver injury by targeting NFκB/NLRP3/IL-1β signaling in rats: Unraveling new roles beyond calcium channel blocking},
journal = {International Immunopharmacology},
year = {2024},
volume = {141},
pages = {113000},
doi = {10.1016/j.intimp.2024.113000}
}
EUVIMED